A Review of Breast Cancer Risk Factors in Adolescents and Young Adults

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Nov 13

PMID 34771713

Citations 5

Authors

Una Mary McVeigh

John William Tepper

Terri Patricia McVeigh

Affiliations

Soon will be listed here.

Abstract

Cancer in adolescents and young adults (AYAs) deserves special consideration for several reasons. AYA cancers encompass paediatric malignancies that present at an older age than expected, or early-onset of cancers that are typically observed in adults. However, disease diagnosed in the AYA population is distinct to those same cancers which are diagnosed in a paediatric or older adult setting. Worse disease-free and overall survival outcomes are observed in the AYA setting, and the incidence of AYA cancers is increasing. Knowledge of an individual's underlying cancer predisposition can influence their clinical care and may facilitate early tumour surveillance strategies and cascade testing of at-risk relatives. This information can further influence reproductive decision making. In this review we discuss the risk factors contributing to AYA breast cancer, such as heritable predisposition, environmental, and lifestyle factors. We also describe a number of risk models which incorporate genetic factors that aid clinicians in quantifying an individual's lifetime risk of disease.

Citing Articles

Benign and malignant breast lesions in children and adolescents - diagnostic and therapeutic approach.

Sosnowska-Sienkiewicz P, Januszkiewicz-Lewandowska D, Mankowski P Front Pediatr. 2024; 12:1417050.

PMID: 39507494 PMC: 11537988. DOI: 10.3389/fped.2024.1417050.

BRCA1/2 mutations and outcomes among Middle Eastern patients with early-onset breast cancer in Oman.

Al Amri W, Al Amri A, Al Abri A, Hughes T, Al Lawati F Oncologist. 2024; 29(12):e1714-e1722.

PMID: 39187384 PMC: 11630774. DOI: 10.1093/oncolo/oyae214.

Traditional Clinicopathological Biomarkers Still Determine Disease-Free and Overall Survival in Invasive Breast Cancer Patients: A Pilot Study.

Wrzeszcz K, Kwiatkowska K, Rhone P, Formanowicz D, Kruszewski S, Ruszkowska-Ciastek B J Clin Med. 2024; 13(7).

PMID: 38610786 PMC: 11012512. DOI: 10.3390/jcm13072021.

System biology mediated assessment of molecular mechanism for sinapic acid against breast cancer: via network pharmacology and molecular dynamic simulation.

Dwivedi P, Shastry C Sci Rep. 2023; 13(1):21982.

PMID: 38081857 PMC: 10713517. DOI: 10.1038/s41598-023-47901-3.

Racial, Lifestyle, and Healthcare Contributors to Perceived Cancer Risk among Physically Active Adolescent and Young Adult Women Aged 18-39 Years.

Brown J, Alalwan M, Absie S, Korley N, Parvanta C, Meade C Int J Environ Res Public Health. 2023; 20(9).

PMID: 37174256 PMC: 10177863. DOI: 10.3390/ijerph20095740.

References

Zhang D, Singh B, Moerland J, Mitchell O, Lockwood L, Carapellucci S . Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice. Sci Rep. 2021; 11(1):1234. PMC: 7806744. DOI: 10.1038/s41598-020-79663-7. View

Evans D, Howard E, Giblin C, Clancy T, Spencer H, Huson S . Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010; 152A(2):327-32. DOI: 10.1002/ajmg.a.33139. View

Thune I, Brenn T, Lund E, Gaard M . Physical activity and the risk of breast cancer. N Engl J Med. 1997; 336(18):1269-75. DOI: 10.1056/NEJM199705013361801. View

Yousef A . Male Breast Cancer: Epidemiology and Risk Factors. Semin Oncol. 2018; 44(4):267-272. DOI: 10.1053/j.seminoncol.2017.11.002. View

Iqbal J, Ragone A, Lubinski J, Lynch H, Moller P, Ghadirian P . The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012; 107(12):2005-9. PMC: 3516682. DOI: 10.1038/bjc.2012.483. View

Morch L, Skovlund C, Hannaford P, Iversen L, Fielding S, Lidegaard O . Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2017; 377(23):2228-2239. DOI: 10.1056/NEJMoa1700732. View

King M, Wieand S, Hale K, Lee M, Walsh T, Owens K . Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001; 286(18):2251-6. DOI: 10.1001/jama.286.18.2251. View

Brennan S, Cantwell M, Cardwell C, Velentzis L, Woodside J . Dietary patterns and breast cancer risk: a systematic review and meta-analysis. Am J Clin Nutr. 2010; 91(5):1294-302. DOI: 10.3945/ajcn.2009.28796. View

Rummel S, Lovejoy L, Shriver C, Ellsworth R . Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer. Breast Cancer Res Treat. 2017; 164(3):593-601. DOI: 10.1007/s10549-017-4291-8. View

10.

Takeichi M, Hirano S, Matsuyoshi N, Fujimori T . Cytoplasmic control of cadherin-mediated cell-cell adhesion. Cold Spring Harb Symp Quant Biol. 1992; 57:327-34. DOI: 10.1101/sqb.1992.057.01.037. View

11.

Brennan S, Woodside J, Lunny P, Cardwell C, Cantwell M . Dietary fat and breast cancer mortality: A systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2015; 57(10):1999-2008. DOI: 10.1080/10408398.2012.724481. View

12.

Ghoumid J, Stichelbout M, Jourdain A, Frenois F, Lejeune-Dumoulin S, Alex-Cordier M . Blepharocheilodontic syndrome is a CDH1 pathway-related disorder due to mutations in CDH1 and CTNND1. Genet Med. 2017; 19(9):1013-1021. DOI: 10.1038/gim.2017.11. View

13.

Rebbeck T, Friebel T, Mitra N, Wan F, Chen S, Andrulis I . Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016; 18(1):112. PMC: 5106833. DOI: 10.1186/s13058-016-0768-3. View

14.

Nevanlinna H, Bartek J . The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006; 25(43):5912-9. DOI: 10.1038/sj.onc.1209877. View

15.

Birch J, Alston R, McNally R, Evans D, Kelsey A, Harris M . Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001; 20(34):4621-8. DOI: 10.1038/sj.onc.1204621. View

16.

van der Post R, Vogelaar I, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N . Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015; 52(6):361-74. PMC: 4453626. DOI: 10.1136/jmedgenet-2015-103094. View

17.

Xia Y, Pao G, Chen H, Verma I, Hunter T . Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J Biol Chem. 2002; 278(7):5255-63. DOI: 10.1074/jbc.M204591200. View

18.

Zhang N, Chen P, Khanna K, Scott S, Gatei M, Kozlov S . Isolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Proc Natl Acad Sci U S A. 1997; 94(15):8021-6. PMC: 21549. DOI: 10.1073/pnas.94.15.8021. View

19.

Protani M, Coory M, Martin J . Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 123(3):627-35. DOI: 10.1007/s10549-010-0990-0. View

20.

Thompson E, Rowley S, Li N, McInerny S, Devereux L, Wong-Brown M . Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. J Clin Oncol. 2016; 34(13):1455-9. DOI: 10.1200/JCO.2015.63.7454. View